It was noteworthy that there was no correlation between the patient outcome and the amount of tumor burden as determined via PSMA-PET/CT imaging (Ferdinandus et al., 2020), suggesting that in the stage of advanced mCRPC, the FDG-defined tumor burden might have a greater impact on the patient’s prognosis than PSMA. This evidence concerns the gene FOLH1 and neoplasm.